FATE THERAPEUTICS INC Available-for-sale Securities, Gross Realized Gain (Loss)
FATE THERAPEUTICS INC (FATE) reported Available-for-sale Securities, Gross Realized Gain (Loss) of $0 for the 3-month period ending 2018-03-31, per its 10-Q filed 2018-05-10.
Discontinued › Income Statement › Other Income
us-gaap:AvailableForSaleSecuritiesGrossRealizedGainLossNet · last filed 2018-05-10
- FATE THERAPEUTICS INC available-for-sale securities, gross realized gain (loss) for the quarter ending 2018-03-31 was $0.00.
- FATE THERAPEUTICS INC available-for-sale securities, gross realized gain (loss) for the quarter ending 2017-12-31 was $0.00.
- FATE THERAPEUTICS INC available-for-sale securities, gross realized gain (loss) for the quarter ending 2017-09-30 was $0.00.
- FATE THERAPEUTICS INC available-for-sale securities, gross realized gain (loss) for the quarter ending 2017-06-30 was $0.00.
- FATE THERAPEUTICS INC available-for-sale securities, gross realized gain (loss) for fiscal 2017 was $0.00.
- FATE THERAPEUTICS INC available-for-sale securities, gross realized gain (loss) for fiscal 2016 was $0.00.
| Period end | Available-for-sale Securities, Gross Realized Gain (Loss) 3 month | Available-for-sale Securities, Gross Realized Gain (Loss) 6 month | Available-for-sale Securities, Gross Realized Gain (Loss) 9 month | Available-for-sale Securities, Gross Realized Gain (Loss) 12 month |
|---|---|---|---|---|
| 2018-03-31 | $0.00 10-Q · filed 2018-05-10 | $0.00 derived: sum of 2 quarters · filed 2018-05-10 | $0.00 derived: sum of 3 quarters · filed 2018-05-10 | $0.00 derived: sum of 4 quarters · filed 2018-05-10 |
| 2017-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-05 | $0.00 derived: sum of 2 quarters · filed 2018-03-05 | $0.00 derived: sum of 3 quarters · filed 2018-03-05 | $0.00 10-K · filed 2018-03-05 |
| 2017-09-30 | $0.00 10-Q · filed 2017-11-01 | $0.00 derived: sum of 2 quarters · filed 2017-11-01 | $0.00 10-Q · filed 2017-11-01 | $0.00 derived: sum of 4 quarters · filed 2018-03-05 |
| 2017-06-30 | $0.00 10-Q · filed 2017-08-14 | $0.00 10-Q · filed 2017-08-14 | $0.00 derived: sum of 3 quarters · filed 2018-03-05 | $0.00 derived: sum of 4 quarters · filed 2018-03-05 |
| 2017-03-31 | $0.00 10-Q · filed 2017-05-15 | $0.00 derived: sum of 2 quarters · filed 2018-03-05 | $0.00 derived: sum of 3 quarters · filed 2018-03-05 | $0.00 derived: sum of 4 quarters · filed 2018-03-05 |
| 2016-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-05 | $0.00 derived: sum of 2 quarters · filed 2018-03-05 | $0.00 derived: sum of 3 quarters · filed 2018-03-05 | $0.00 10-K · filed 2018-03-05 |
| 2016-09-30 | $0.00 10-Q · filed 2017-11-01 | $0.00 derived: sum of 2 quarters · filed 2017-11-01 | $0.00 10-Q · filed 2017-11-01 | |
| 2016-06-30 | $0.00 10-Q · filed 2017-08-14 | $0.00 10-Q · filed 2017-08-14 | ||
| 2016-03-31 | $0.00 10-Q · filed 2016-05-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |